Isolation of targeting nanobodies against co-opted tumor vasculature

Laboratory Investigation

Volumn 90, Issue 1, 2010, Pages 61-67

  Roodink, Ilse ^a   Franssen, Maarten ^a   Zuidscherwoude, Malou ^a   Verrijp, Kiek ^a   Van Der Donk, Tom ^b   Raats, Jos ^b   Leenders, William Pj ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Glioma; In vivo biopanning; Nanobody; Phage display; Vascular targeting

Indexed keywords

ANTIBODY; NANOBODY; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANTIBODY ISOLATION; ARTICLE; BIOPANNING; BRAIN BLOOD VESSEL; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MOLECULAR CLONING; MOLECULAR LIBRARY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; ANTIBODY FORMATION; BLOOD VESSELS; BRAIN NEOPLASMS; CAMELIDS, NEW WORLD; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; NEOPLASM TRANSPLANTATION; PEPTIDE LIBRARY; TRANSPLANTATION, HETEROLOGOUS;

EID: 73349136598     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.107     Document Type: Article

References (36)

1. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997;32:253-265.
2. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
3. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-225.
4. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007;114:443-458.
5. Ali SA, McHayleh WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 2008;109:268-272.
6. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173-180.
7. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-6628.
8. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-314.
9. Claes A, Wesseling P, Jeuken J, et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008;7:71-78.
10. Claes A, Gambarota G, Hamans B, et al. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 2008;122:1981-1986.
11. Claes A, Schuuring J, Boots-Sprenger S, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 2008;18:423-433.
12. Roodink I, van der LJ, Kusters B, et al. Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 2006;119:2054-2062.
13. Leenders WP, Kusters B, Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004;10:6222-6230.
14. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-579.
15. Castellani P, Borsi L, Carnemolla B, et al. Differentiation between high-and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002;161:1695-1700.
16. Roodink I, Raats J, van der Zwaag B, et al. Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy? Cancer Res 2005;65:8317-8323.
17. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23:1105-1116.
18. Kolonin MG, Sun J, Do KA, et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006;20:979-981.
19. Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998;102:430-437.
20. van Kempen LC, Leenders WP. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. Eur J Cell Biol 2006;85:61-68.
21. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-448.
22. Huang L, Gainkam LO, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008;10:167-175.
23. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004;64: 2853-2857.
24. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008;7:2288-2297.
25. van KS, de HH, de KP, et al. Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy. J Immunol Methods 2003;279:149-161.
26. Kreis TE. Microinjected antibodies against the cytoplasmic domain of vesicular stomatitis virus glycoprotein block its transport to the cell surface. EMBO J 1986;5:931-941.
27. Kristensen P, Winter G. Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des 1998;3:321-328.
28. Raats J, van Bree N, van Woezik J, et al. Generating recombinant anti-idiotypic antibodies for the detection of haptens in solution. J Immunoassay Immunochem 2003;24:115-146.
29. Kusters B, Leenders WP, Wesseling P, et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002;62: 341-345.
30. Leenders W, Kusters B, Pikkemaat J, et al. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int J Cancer 2003;105:437-443.
31. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
32. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
33. Dienst A, Grunow A, Unruh M, et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005;97:733-747.
34. Schraa AJ, Kok RJ, Moorlag HE, et al. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 2002;102:469-475.
35. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-6151.
36. Dijkgraaf I, Kruijtzer JA, Frielink C, et al. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 2007;120:605-610.